Ardelyx Inc

ARDX is entrenched in a Stage 4 decline with a bearish medium-term bias confirmed by active lower-highs and lower-lows under declining EMAs. Price is pulling back into the dynamic 9/21/50 EMA resistance zone from oversold conditions, providing a clear sell execution area. Under our Speculative strategy’s high-selectivity framework, we will execute immediate sells at this resistance on visible rejection rather than waiting for further downside.

• ↑Total revenue grew 38% YoY to $93.4M; Ibsrella sales up 58%.
• ↑Cash balance of $238.1M supports R&D and commercial expansion.
• ↓Operating expenses could reach $520M in 2026, net loss $37.6M.